Newron Pharmaceuticals

Newron Pharmaceuticals SpA: Expanding Global and U.S. Investor & Partner Visibility

Newron is a Swiss-traded biopharmaceutical company focused on therapies for patients with diseases of the CNS.
New breakthrough data presented supporting that evenamide for schizophrenia impacts long-term brain plasticity changes in its extended therapeutic actions.
Build global visibility and, expand understanding with, sell-side analysts, potential partners/licensees, investors and investment banking community.

Execute a globally viewed scientific and investor-oriented R&D Day to increase investor and partner visibility.
Develop a US-centric marketing strategy for the event, including message and presentation development, event and location branding and broadcast.
Audience acquisition through extensive media relations, press release distribution, focused email campaigns and personal investor and partner outreach.

Secured the participation of the world’s leading experts in neurobiology, psychiatry and schizophrenia as speakers.
Live video of three leading schizophrenia KOL experts, elevating Newron’s presence and market shaping
35 in-person attendees, including representatives from 5 investment banks and 9 sell-side analysts.
More than 200 live webcast participants from 7 countries worldwide.
Global webcast of event listened to for more than 700 total hours in more than 400 live and on-demand sessions